Gilead 2nd-qtr sales leap 21%, lifted by Veklury and Biktarvy

30 July 2021

US biotech major Gilead Sciences (Nasdaq: GILD) yesterday posting financials for second-quarter 2021, showing that revenues of $6.2 billion increased 21% compared to the same period in 2020, boosted by high demand for its COVID-19 treatment Veklury (remdesivir), and Biktarvy (bictegravir/FTC/tenofovir alafenamide (TAF).

Diluted earnings per share (EPS) increased to $1.21 for the second quarter 2021 compared to net loss per share of $2.66 for the same period in 2020. Non-generally-accepted accounting principles (GAAP) diluted EPS increased 68% to $1.87, primarily due to higher operating income partially offset by lower interest income. The results were announced after markets closed, and Gilead’s shares went down 2.2% to $68.30 in after-hours trading.

Gilead has updated its full-year guidance, and now expects:

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK